Evidence map›Paper›PMID 41534012›Full record

Observational studyNeurology2026

Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia.

Lachlan Cribb, Margarita Moreno-Betancur, Matthew Paul Pase, Rory Wolfe, Carlene Britt, Zhen Zhou, Raj C Shah, Gary Rance, Kerry M Sheets, Trevor T-J Chong and 4 more

Erratum issuedAbstract readObservational Study
In one paragraph

Observational study in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lachlan CribbSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0001-5276-5249
Margarita Moreno-BetancurClinical Epidemiology & Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia.
Matthew Paul PaseSchool of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.ORCID 0000-0002-4143-8485
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-2126-1045
Carlene BrittSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Zhen ZhouSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-0835-8686
Raj C ShahDepartment of Family & Preventive Medicine and the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL.ORCID 0000-0001-9706-9730
Gary RanceDepartment of Audiology and Speech Pathology, The University of Melbourne, Australia.
Kerry M SheetsDepartment of Medicine, Hennepin Healthcare, Minneapolis, MN.ORCID 0000-0002-3492-2404
Trevor T-J ChongTurner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Australia.ORCID 0000-0001-7764-3811
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-1249-6149
Anne M MurrayBerman Center for Outcomes & Clinical Research, Hennepin HealthCare Research Institute, Minneapolis, MN.ORCID 0000-0002-2787-8433
Alice OwenSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Joanne RyanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-7039-6325

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHearing loss is a risk factor of cognitive decline and dementia. We sought to investigate the effect of hearing aid (HA) use on cognition and dementia risk in older adults with hearing impairment.

methodsWe emulated a target trial using data from Australian participants of the ASPirin in Reducing Events in the Elderly study. In the target trial, eligible participants were dementia-free, had moderate hearing impairment, and had no previous HA use. The treatment strategies were "use HAs" and "do not use HAs." Outcomes included overall cognition, dementia (DSM-IV criteria), and cognitive impairment (cognitive decline or dementia). The emulation used new HA prescription and frequency-of-use data measured by questionnaire, as well as cognition data from semiannual assessments over 7 years. Self-reported hearing problems were used as a proxy for moderate hearing impairment. Using the parametric g-formula, we estimated observational analogs of the intention-to-treat effect, using HA prescription to emulate allocation. Analyses for cognition outcomes were restricted to survivors. Multiple imputation was used for missing covariate and cognitive outcome data. We also emulated a second target trial with treatment strategies of (1) never, (2) rarely/sometimes, and (3) often/always use HAs.

resultsAcross imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. The mean age was 75 years, and 48% were female. The estimated 7-year mean overall cognition scores among survivors were similar under HA prescription and no HA prescription (mean difference 0.03 SDs; 95% CI -0.14 to 0.21). The estimated 7-year risk of dementia was 5.0% under HA prescription and 7.5% under no HA prescription (risk ratio [RR] 0.67; 95% CI 0.37-0.97), and that of cognitive impairment was 36.1% under HA prescription and 42.4% under no HA prescription (RR 0.85; 95% CI 0.70-1.00). The risks of dementia and cognitive impairment were inversely associated with the frequency of HA use. DISCUSSION: We found that HA use in older people with hearing impairment may reduce dementia risk, although differences in age-related cognitive change were insubstantial. We cannot rule out residual confounding as an explanation for our findings. Long-term randomized trials of HAs for dementia risk are justified. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the use of hearing aids did not change overall cognitive scores in people 70 years and older with moderate hearing impairment as compared to those who used hearing aids.

Indexed as

Cognitive DysfunctionDementiaHearing AidsHearing LossAgedAged, 80 and overAustraliaFemaleHumansMaleRandomized Controlled Trials as Topic

Identifiers

PMID41534012
PMCPMC13038394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.